X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration is employing QUANTRO’s drug discovery platform based on time-resolved transcriptomics to identify drug candidates interfering with key transcriptional programs in cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: QUANTRO Therapeutics
Deal Size: $544.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 04, 2024
Details:
Under the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo (adalimumab-adbm) injection and Adalimumab-adbm.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Cyltezo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Quallent Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 13, 2024
Details:
BI 764524 is a humanized monoclonal anti-Sema3A antibody intended to re-vascularize ischemic areas and reduce leakage in the retina, offering the potential to address retinal non-perfusion in retinal diseases.
Lead Product(s): BI 764524
Therapeutic Area: Ophthalmology Product Name: BI 764524
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2024
Details:
Cyltezo (adalimumab-biosimilar) is a tumor necrosis factor (TNF) blocker indicated for treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult crohn’s disease, ulcerative colitis & plaque psoriasis.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Cyltezo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
The partnership is focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
Lead Product(s): RNA-based Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Ochre Bio
Deal Size: $1,035.0 million Upfront Cash: $35.0 million
Deal Type: Partnership April 22, 2024
Details:
Jardiance (empagliflozin) is an oral inhibitor of sodium-glucose co-transporter 2 (SGLT2) inhibitor, which is being evaluated for the treatment of myocardial infarction.
Lead Product(s): Empagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2024
Details:
Spevigo (spesolimab) is a novel, humanized, selective antibody that specifically blocks activation of the IL-36R, a signaling pathway within the immune system. It is approved for the treatment of generalized pustular psoriasis in adults and pediatric patients aged 12 & above.
Lead Product(s): Spesolimab
Therapeutic Area: Dermatology Product Name: Spevigo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
The collaboration aims to focus on the development of HTL0048149, which is a GPR52 agonist. Currently it being evaluated with patients for the treatment of Schizophrenia.
Lead Product(s): HTL0039732
Therapeutic Area: Psychiatry/Psychology Product Name: HTL0039732
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Sosei Heptares
Deal Size: $732.5 million Upfront Cash: $27.3 million
Deal Type: Collaboration March 11, 2024
Details:
BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): Survodutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BI 456906
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Zealand Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
NBL-001 (volasertib) is a PLK-1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory acute myelogenous leukemia.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Notable Labs
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
